Headlands Technologies LLC Acquires Shares of 7,754 VanEck Biotech ETF $BBH

Headlands Technologies LLC acquired a new position in shares of VanEck Biotech ETF (NASDAQ:BBH) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 7,754 shares of the company’s stock, valued at approximately $1,576,000. Headlands Technologies LLC owned approximately 0.40% of VanEck Biotech ETF at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. grew its stake in VanEck Biotech ETF by 40,463.3% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 494,061 shares of the company’s stock worth $93,506,000 after purchasing an additional 492,843 shares in the last quarter. Quantitative Investment Management LLC acquired a new stake in VanEck Biotech ETF during the second quarter valued at approximately $7,589,000. Raymond James Financial Inc. lifted its holdings in VanEck Biotech ETF by 2.8% during the 3rd quarter. Raymond James Financial Inc. now owns 69,809 shares of the company’s stock worth $11,566,000 after buying an additional 1,869 shares during the last quarter. Bank of America Corp DE grew its position in shares of VanEck Biotech ETF by 44.3% in the 1st quarter. Bank of America Corp DE now owns 66,338 shares of the company’s stock worth $12,473,000 after acquiring an additional 20,375 shares in the last quarter. Finally, Ascent Advisors LLC acquired a new position in shares of VanEck Biotech ETF in the 1st quarter worth approximately $11,178,000. Institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Price Performance

BBH stock opened at $235.50 on Tuesday. The stock’s 50 day simple moving average is $213.87 and its 200 day simple moving average is $197.38. VanEck Biotech ETF has a 12-month low of $160.91 and a 12-month high of $244.35.

Insiders Place Their Bets

In other VanEck Biotech ETF news, major shareholder Sardar Biglari sold 2,749 shares of the stock in a transaction on Thursday, July 16th. The shares were sold at an average price of $16.70, for a total transaction of $45,908.30. Following the sale, the insider directly owned 3,549,961 shares of the company’s stock, valued at approximately $59,284,348.70. This represents a 0.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 10,493 shares of company stock worth $175,335 in the last three months.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.